Search
When an immune cell faces a foe, it has more than chemical weapons at its disposal.
Learn about how the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) could provide a new option for patients with metastatic renal cell carcinoma.
Two studies on multiple myeloma provide new information about diagnosing and treating this blood cancer.
Sloan Kettering Institute investigators have found that a subpopulation of cells within a type of sarcoma called malignant peripheral nerve sheath tumor appear to be similar to a type of neural stem cells.
Patients with secondary rectal cancer after radiotherapy for prostate cancer have shorter survival compared with matched treatment-naïve patients. However, a new study by investigators at MSK has found distinct differences in patient characteristics, available treatment options, and tumor biologic characteristics that may explain the gap.
Learn about Anna-Katerina “Kat” Hadjantonakis, who is Chair of the Sloan Kettering Institute’s Developmental Biology Program.
Samuel Singer has been appointed Chief of the Gastric and Mixed Tumor Service in the Department of Surgery.
There are more than 100 subtypes of brain tumors, making them a challenge to accurately diagnose. Now researchers have figured out a way to reliably distinguish them.
VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.
An MSK clinical trial found that participating in integrative therapy classes online could benefit cancer patients in active treatment, not only by reducing fatigue, anxiety, and depression but also lowering hospitalization rates.